InstructorOffice: Guyton Building, G454Lab: (601) 815-1402Office: (601) 815-1402
My research interest is in the areas of renal physiology, cardiovascular physiology, pregnancy physiology, and fetal programming. It is estimated that approximately 70 million people (1 out of 3 adults) in America have hypertension, with 50% of these people having no control over their blood pressure.
Preeclampsia, pregnancy induce hypertension, is a serious disease that effects about 3-5% of all births each year in the United States. Women with preeclampsia are at a 5-12 fold increased risk of developing end-stage renal disease, 2 fold risk of stroke, and 2 fold risk of developing a cardiovascular disease later in life. Furthermore women with preeclampsia have an increased production of agonistic autoantibodies to the Angiotensin II type 1 receptor (AT1-AA) and Tumor necrosis factor alpha (TNFα). The goal of my research is to determine if blockade AT1-AA and TNFα improves pregnancy outcomes and the risk of disease development later in life for preeclamptic mothers. The potential impact of this study is that blockade of the AT1-AA and/or TNFα during pregnancy may serve as a novel therapy against preeclampsia and the risk of disease development later in life for preeclamptic mothers.